Brandy Comyford’s Post

Lamassu BioTech is ready for Biotechnology Innovation Organization’s #BIO2024 Conference! 🔬 Lamassu CEO Gabi Hanna MD., will be in San Diego throughout #BIO2024, meeting with other leaders in the #biotech industry and exploring opportunities to accelerate hope and healing. Lamassu is transforming the way we treat metastatic cancer and solving the critical unmet medical need of severe acute pancreatitis. SA53, a #noveltherapeutic that targets p53 wild-type sarcomas, has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission that was recently approved by the FDA. This potential best-in-class #precisionmedicines offers new hope for #metastitic #cancertreatment. Companies and investors interested in targeted cancer therapies, or anyone interested in learning about our team’s works, should use the contact form on our website, https://lnkd.in/gnvwYBm, to schedule a meeting during #BIO2024.

At #WorldADC San Diego and want to learn more about our Click Activated Protodrugs Against Cancer platform and how this pre-targeting approach can overcome dose limiting off-target toxicities associated with ADCs?    Look no further than today’s poster session where we’ll be presenting two posters.     Discover how our pre-targeting approach achieves increased tumor-targeted drug exposure while sparing healthy tissues, creating a greater therapeutic index. You can also learn why CEACAM5 is an ideal target for our technology.    Come meet our team, including José M. Mejía Oneto, Travis Biechele, Jesse McFarland, Mukul Agarwal, and Michael Zakharian and explore the future of targeted therapeutics.     #clickchemistry #adc #drugdevelopment #biotech #innovation #research

Pillar Biosciences Incorporated and AstraZeneca have announced a partnership to advance NGS-based liquid biopsy testing in Europe! 🌍🔬 This new partnership aims to leverage Pillar Biosciences Incorporated OncoReveal LBx panel to rapidly identify tumors with clinically actionable genomic alterations via liquid biopsy profiling while supporting faster diagnostic testing. "Access to cost effective, easy to use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally," - Dan Harma 👏 Great to see another partnership like my post last week on Illumina, Bayer & Eli Lilly and Company! 👏👏👏 #CancerResearch #LiquidBiopsy #HealthcareInnovation #Partnership #PersonalizedMedicine #NGS

LSX USA Congress Biotech company showcase pt.3 OCMS Bio! 👨💻 Today we venture into the more 'techbio' side of Biotech 🌟OCMS Bio deploys a proprietary mammalian high throughput antibody discovery engine for the rapid development of patentable best-in-class fast-follower mAbs with improved efficacy for therapeutically proven high value targets.   Since launching this program in January, 3 validated preclinical leads (in infectious disease, oncology and human metabolism) are coming off our pipeline this summer with 6 more finishing in the next 18 months--each a marked improvement over an in market, best in class antibody.   These fast-follower best-in-class molecules offer increased efficacy, access and patient choice globally.🌟 Every presenting company does something different, but all are innovators driving the industry forward. Lets continue to Invest in Innovation! We look forward to welcoming you in September Paul Halpern #lsxusa #techbio #investment #biotech #antibodies #partnering #biopharma

𝐇𝐮𝐦𝐚𝐧𝐢𝐳𝐞𝐝 𝐌𝐨𝐮𝐬𝐞 𝐚𝐧𝐝 𝐑𝐚𝐭 𝐌𝐨𝐝𝐞𝐥𝐬: 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 Download PDF Brochure @ bit.ly/3L91jK7 The global humanized mouse and rat model market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028. Alloy Therapeutics, Inc.      Champions Oncology, Inc.      Biocytogen      GemPharmatech      TransCure bioServices       T-Therapeutics Ltd    Ozgene Cyagen Aragen Life Sciences GemPharmatech Asia Pacific The Jackson Laboratory Taconic Biosciences, Champions Oncology, Inc. Hera BioLabs genOway Inotiv ingenious targeting laboratory Trans Genic Inc Harbour Antibodies Oncodesign Services Pharmatest Services Ozgene TransCure bioServices Aragen Life Sciences #humanizedmouse #humanizedrat #mousemodelmarket #ratmodelmarket #humanizedanimalmodels #biomedicalresearch #drugdevelopment #precisionmedicine #humanizationtechnology

Our work, titled "Machine Learning-Based Prediction of Lung Cancer Using Biomarker Data," ably presented by Uma J. was awarded Best Oral Presentation at the International Conference on Biotechnology and Biomedical Research held on September 19-20, 2024, in Goa, India, organized by the Association of Pharmaceutical Research (APR). This work focuses on leveraging AI to enhance early detection of lung cancer through non-invasive biomarker analysis. Manasi Kulkarni-Khasnis Snahlata Singh Atharva Joshi Jahnavi Kulkarni Jaithya Suseel A heartfelt thanks to the organizers, fellow researchers, and attendees for the enriching discussions and feedback. This recognition inspires us to continue innovating at the intersection of AI and healthcare to drive impactful outcomes. #MachineLearning #LungCancer #Biotechnology #BiomedicalResearch #AIinHealthcare #CancerResearch #APR2024

We’re looking forward to being in Boston next month for PEGS, one of the most important protein and antibody engineering events of the year. We’ll be sharing a presentation as part of the Emerging Targets for Oncology and Beyond track on Wednesday 5/15 at 10am; come find out "What’s Wrong With This Picture? The Danger of Inadequate Screens in Antibody Discovery." We also want to hear about your upcoming projects, and talk about how we can work together to help you discover more, discover faster, and discover better. Click below and let us know when’s a good time to get together in Boston. https://hubs.li/Q02tCtBQ0 #PEGSBoston #antibodydiscovery #PEGS24

The number of ADCs showing promising outcomes in clinical trials is rapidly growing, offering exciting opportunities for cancer patients. The inaugural Engineering Conjugates conference ( https://lnkd.in/egpzyeYZ) at #PEGSEurope brings leaders in the field together to share innovations in next-gen #ADC formats to enhance #payload delivery and improve #therapeuticindex. Hear progress in bispecific ADCs, peptide/fragment-based ADCs, dual-payloads, novel targets such as Nectin-4, CEACAM5C and more! Speakers include: Yves BAUDAT, Sanofi Ulrich Brinkmann, Roche Innovation Center Munich Jutta Deckert, Iksuda Therapeutics Mahendra Deonarain, Antikor Biopharma Nimish Gera, Mythic Therapeutics Kim Holmstrøm, Bioneer AS Ilias Koutsopetras, University of Strasbourg Sara Mangsbo, Uppsala University Diane Retallack, Primrose Bio Min Shan 单旻, Merck KGaA Caroline Soulas, Innate Pharma Philipp Spycher, Araris Biotech Ralf Strasser, Bruker Biosensors Obinna C Ubah, Elasmogen Ltd Sandra Uhlenbroich, Bicycle Therapeutics #proteinengineering #Antibodydrugconjugates #noveltargets

Our (www.accelerobio.com) Oral presentation on “Speeding up drug discovery with high-quality and high-reliability crystallography-based library screening” at the 74th annual meeting of the American Crystallographic Association conference in Denver next week, including an emphasis on how this approach has resulted in hits and rapid advancement to leads against the undruggable DDR endonuclease APE1 showing promise in cellular assays of glioblastoma and ovarian and breast cancers at our partner XPose Therapeutics. Key: simultaneous discovery and production of hits, co-crystal structures, novel sites, allosteric sites, targeting undruggables, for small molecule modulators and targeted protein degradation, by our protein X-ray crystallography-driven drug discovery and feeding into our Analytics/ML/AIDD (AI Drug Discovery). #drugdiscovery #therapeutics #oncology #structuralbiology

The H1 2024 report is now available on our website 📈 Here are some of the highlights: 🔬 Molecure focused on the development of two key molecules: #OATD01 and #OATD02, as well as expanding research activities based on, among other things, advanced artificial intelligence technologies 💊 Molecure received approval to initiate a Phase II clinical trial #KITE for #OATD01 for the treatment of pulmonary sarcoidosis in the EU and Norway. Prior to that, Molecure received approval from the US FDA and the UK MHRA 👩⚕️ Progress in the Phase I clinical trial of #OATD02, for the treatment of cancer, recruitment continues and addition of 3 more patients is underway 🤝 Strategic research collaboration with Avicenna Biosciences to optimize small-molecule drug discovery and development processes in the USP7 program 🧬 Confirmation of the ability of a second molecule, developed within the mRNA platform, to effectively bind to an established mRNA fragment and block the translation process of a pathogenic protein Click here to view the full report (section "Raporty giełdowe") ➡️ https://lnkd.in/djcwrXGn